Overview

VEC-162 Study in Adult Patients With Primary Insomnia

Status:
Completed
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of a 5 week double-blind treatment period of VEC-162 as compared to placebo in male and female patients with primary insomnia.
Phase:
Phase 3
Details
Lead Sponsor:
Vanda Pharmaceuticals